Trial Profile
A Randomized, Double-blind, Cross-over Trial in Patients With Irritable Bowel Syndrome Investigating the Efficacy and Safety of PPC-5650 on Sensation and Pain During Standardized Stimulation of the Rectosigmoid.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2014
Price :
$35
*
At a glance
- Drugs PPC 5650 (Primary)
- Indications Irritable bowel syndrome; Pain
- Focus Therapeutic Use
- Sponsors Aros Pharma
- 20 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Jan 2012 Planned end date changed from 1 Mar 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 19 Jan 2012 Actual initiation date (Jan 2012) added as reported by ClinicalTrials.gov.